[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"updates-archive-2026-04-27-8":3},{"date":4,"filings":5,"has_more":114,"limit":115,"page":116,"total_count":117},"2026-04-27",[6,14,21,28,35,42,49,56,61,66,73,78,85,92,97,104,109],{"company_name":7,"filing_date":8,"filing_source":9,"headline":10,"id":11,"stock_code":12,"summary_text":13},"Elecon Engineering Company Limited","2026-04-27T09:46:39.345000","NSE","Addresses Stock Price Volatility Inquiry","69eee356f35e30561cff5b0b","ELECON","*   Responding to an inquiry from the National Stock Exchange (NSE) regarding significant movement in its stock price.\n*   Stated that there is no undisclosed information or pending announcement that could explain the recent price and volume behavior.\n*   The company affirms it is not connected with the price movement and is in compliance with all disclosure regulations.\n*   **Key takeaway for investors:** The unexplained volatility, which triggered the exchange's inquiry, is a red flag. The company's denial suggests the movement may be driven by market speculation rather than company fundamentals.",{"company_name":15,"filing_date":16,"filing_source":9,"headline":17,"id":18,"stock_code":19,"summary_text":20},"Larsen & Toubro Limited","2026-04-27T09:36:39.264000","L&T Strengthens Realty Arm with Gurugram Acquisition & Consolidation Plan","69eee0f45236ec998939bd61","LT","*   L&T's subsidiary, L&T Realty, has acquired 100% of International Green Scapes Ltd, marking its first entry into the NCR (National Capital Region) real estate market.\n*   The acquisition includes 20 acres of land in Gurugram, adding a development potential of approximately 3.6 million square feet to its portfolio.\n*   L&T has also initiated a process to consolidate all its realty businesses into a single, unified entity, subject to regulatory approvals.\n*   Including other recent acquisitions, the company has added a total of 6.6 million square feet of new development potential to its pipeline.",{"company_name":22,"filing_date":23,"filing_source":9,"headline":24,"id":25,"stock_code":26,"summary_text":27},"Anlon Healthcare Limited","2026-04-27T09:31:39.641000","Completes 1:1 Bonus Share Allotment","69eedfdaec7f5de862c53a40","544497","*   The company has successfully allotted Bonus Equity Shares in a 1:1 ratio (one new share for every one existing share).\n*   The allotment was finalized on April 27, 2026, for shareholders on record as of April 24, 2026.\n*   As a result, the company's paid-up share capital has doubled to **₹ 1,06,30,30,000**.\n*   The total number of equity shares now stands at **53,15,15,000**.",{"company_name":29,"filing_date":30,"filing_source":9,"headline":31,"id":32,"stock_code":33,"summary_text":34},"Bharat Forge Limited","2026-04-27T09:21:39.261000","Achieves Major Milestone with New Armoured Vehicle Platform","69eedd75f35e30561cff5af9","BHARATFORG","*   Announced the flag-off of its \"Vikram VT 21\" project, unveiling two new advanced armoured platforms developed in partnership with DRDO and Tata Advanced Systems.\n*   Crucially, the platform has cleared the Ministry of Defence's Technical Evaluation Committee (TEC), a significant step towards securing future procurement orders.\n*   The company highlighted the rapid development, moving from concept to a combat-ready platform in under three years.\n*   The platforms are designed for the Indian Armed Forces and are also ready for the global export market, opening up new revenue streams.",{"company_name":36,"filing_date":37,"filing_source":9,"headline":38,"id":39,"stock_code":40,"summary_text":41},"Veranda Learning Solutions Limited","2026-04-27T09:16:39.187000","Shareholders Approve Demerger of Commerce Business, Eyeing Separate Listing","69eedc4dabd16353d2ff5b91","VERANDA","*   Equity shareholders have approved the demerger of the company's \"Commerce Vertical\" into a separate entity named J.K.Shah Commerce Education Limited.\n*   This move paves the way for a potential separate stock exchange listing of the new commerce entity, a key step aimed at unlocking shareholder value.\n*   Management's stated goal is to create focused, high-growth businesses with greater agility and sharper execution.\n*   The demerger scheme now requires final sanction from the National Company Law Tribunal (NCLT) to be completed.",{"company_name":43,"filing_date":44,"filing_source":9,"headline":45,"id":46,"stock_code":47,"summary_text":48},"Transformers And Rectifiers (India) Limited","2026-04-27T09:16:39.151000","TARIL Reports Record Revenue & Enters HVDC Market, But Faces Execution Hurdles","69eedc675236ec998939bd4f","TARIL","- **Strong FY26 Performance:** Consolidated revenue grew 24.3% to ₹2,509 Crores, with the company achieving its highest-ever production of 33,763 MVA.\n- **Robust Order Book:** The unexecuted order book stands at over ₹5,000 Crores, providing strong revenue visibility for the next 18 months.\n- **Strategic HVDC Entry:** Secured a landmark HVDC transformer repair order from PGCIL, a first for an Indian company, which is a key step toward becoming an approved HVDC manufacturer.\n- **Ambitious FY27 Guidance:** Management guides for revenue of \"around INR 3,250 crores\" for FY27, implying 35-40% growth, with EBITDA margins expected at 16.5% to 17%.\n- **Key Risks & Red Flags:** The company noted a delay in its Changodar plant expansion, has a history of missing guidance (which was questioned by investors), and has a pending unresolved issue with the World Bank.",{"company_name":50,"filing_date":51,"filing_source":9,"headline":52,"id":53,"stock_code":54,"summary_text":55},"Cohance Lifesciences Limited","2026-04-27T09:11:39.183000","Major Leadership Change: Appoints Former Cipla CEO as New Executive Chairman & Group CEO","69eedb195236ec998939bd49","COHANCE","*   \u003Cb>New Leadership:\u003C\u002Fb> Mr. Umang Vohra, former CEO & MD of Cipla, has been appointed as the new Executive Chairman and Group CEO, effective May 2026.\n*   \u003Cb>Executive Departure:\u003C\u002Fb> Mr. Vivek Sharma is stepping down as Executive Chairman for personal reasons.\n*   \u003Cb>Smooth Transition:\u003C\u002Fb> Mr. Sharma will continue as an Advisor for the next 9 months to support a smooth transition and ensure leadership continuity.\n*   \u003Cb>Strategic Rationale:\u003C\u002Fb> The appointment is a key strategic move to lead the company's \"next phase of transformation and growth\" and build a leading technology-driven CDMO platform.",{"company_name":43,"filing_date":57,"filing_source":9,"headline":58,"id":59,"stock_code":47,"summary_text":60},"2026-04-27T09:06:39.443000","Secures ₹150 Crore Export Order","69eed9f3f35e30561cff5aed","*   Secured a new export order from an international entity, PDC AK LPIV, LLC.\n*   The total value of the order is approximately **₹150 Crore** (USD 16.26 Million).\n*   The contract is for the manufacturing of 5 transformers and related work.\n*   The order is scheduled for delivery by mid-2027, enhancing revenue visibility.",{"company_name":50,"filing_date":62,"filing_source":9,"headline":63,"id":64,"stock_code":54,"summary_text":65},"2026-04-27T09:01:40.021000","New Chairman & CEO Appointed; Board Approves Major ESOP Plan","69eed8c8a157653c6639bdc4","• \u003Cb>Leadership Change:\u003C\u002Fb> Executive Chairman Mr. Vivek Sharma has resigned, effective April 30, 2026. He will continue as a Special Advisor for 9 months to ensure a smooth transition.\n• \u003Cb>New Appointments:\u003C\u002Fb> Mr. Umang Vohra has been appointed as the new Chairman (effective May 1, 2026) and Group CEO (effective May 20, 2026).\n• \u003Cb>New ESOP Plan:\u003C\u002Fb> The Board approved the \"ESOP 2026\" plan, creating a pool of 25.9 million options, subject to shareholder approval.\n• \u003Cb>Shareholder Dilution:\u003C\u002Fb> The new plan represents a potential 6.25% dilution. The total dilution from all ESOPs is expected to be capped at 7.75% over 7.5 years.\n• \u003Cb>Next Steps:\u003C\u002Fb> The appointment of Mr. Vohra and the new ESOP plan are subject to shareholder approval via a postal ballot.",{"company_name":67,"filing_date":68,"filing_source":9,"headline":69,"id":70,"stock_code":71,"summary_text":72},"Tata Elxsi Limited","2026-04-27T09:01:39.304000","CFO Transition Announced","69eed8bbf35e30561cff5ae9","TATAELXSI","*   Mr. Gaurav Bajaj will step down as Chief Financial Officer (CFO), effective May 29, 2026.\n*   Mr. Nalin Rana has been appointed as the new CFO, effective May 30, 2026.\n*   Mr. Rana is a senior leader from the Tata Sons Group CFO and Strategy Office, with 17 years of experience in strategic finance, corporate strategy, and investment banking.",{"company_name":67,"filing_date":74,"filing_source":9,"headline":75,"id":76,"stock_code":71,"summary_text":77},"2026-04-27T08:51:39.618000","Tata Elxsi Appoints New Chief Financial Officer","69eed66df43b112c8d91d7bf","*   Mr. Gaurav Bajaj has resigned as Chief Financial Officer (CFO), effective May 29, 2026, to pursue other career opportunities.\n*   The Board has appointed **Mr. Nalin Rana** as the new CFO, effective May 30, 2026.\n*   Mr. Rana is a senior leader from the Tata Sons Group CFO and Strategy Office, bringing 17 years of experience in strategic finance, M&A, and investment banking.\n*   The appointment is viewed positively, signaling strong group-level oversight and the strategic importance of Tata Elxsi within the Tata ecosystem. A smooth transition is planned.",{"company_name":79,"filing_date":80,"filing_source":9,"headline":81,"id":82,"stock_code":83,"summary_text":84},"Jagsonpal Pharmaceuticals Limited","2026-04-27T07:46:39.189000","Shareholders Approve ₹40 Crore Buyback at ₹250\u002FShare","69eec737f35e30561cff5abb","JAGSNPHARM","*   Shareholders have approved the company's proposal to buy back its equity shares.\n*   The buyback will be for an aggregate amount of up to ₹ 40 Crores at a price of ₹ 250 per share.\n*   The stated rationale is to enhance shareholder value, optimize capital structure, and improve Earnings Per Share (EPS).\n*   The company will announce the record date and timelines for the buyback in due course.",{"company_name":86,"filing_date":87,"filing_source":9,"headline":88,"id":89,"stock_code":90,"summary_text":91},"Premier Energies Limited","2026-04-27T07:41:39.218000","Launches India's First All-Black Solar Module","69eec6075236ec998939bd06","PREMIERENE","• Announced the launch of the \"NeoBlack Series,\" India's first all-black G12R DCR solar module, targeting the residential and premium commercial rooftop market.\n• The new module features high power output (up to 630 Wp), next-gen TOPCon cell technology, and a 30-year power output warranty.\n• This launch provides a first-mover advantage and aligns with government initiatives like \"PM Surya Ghar,\" aiming to capture growing demand by addressing aesthetic concerns in rooftop solar.",{"company_name":79,"filing_date":93,"filing_source":9,"headline":94,"id":95,"stock_code":83,"summary_text":96},"2026-04-27T07:26:39.144000","Share Buyback Approved by Shareholders","69eec286f43b112c8d91d777","*   Shareholders have approved a proposal for the company to buy back up to **16,00,000 equity shares**.\n*   The buyback price is fixed at **₹250 per share**, with a total outlay not exceeding **₹40 crores**.\n*   The Special Resolution was passed with an overwhelming majority of **99.99%** of votes in favour.\n*   This action is a strategic move to return surplus cash to shareholders and may increase Earnings Per Share (EPS) for remaining investors.",{"company_name":98,"filing_date":99,"filing_source":9,"headline":100,"id":101,"stock_code":102,"summary_text":103},"Sun Pharmaceutical Industries Limited","2026-04-27T06:36:39.439000","To Acquire Organon & Co. in a Transformative $11.75 Bn Deal","69eeb6d9f43b112c8d91d751","SUNPHARMA","*   Announced the proposed acquisition of Organon & Co. for an Enterprise Value of **$11.75 Bn** ($14.0 per share).\n*   The deal will create a combined entity with pro-forma revenue of **~$12.4 Bn** and EBITDA of **~$3.7 Bn**, effectively doubling the company's scale.\n*   Strategically, the acquisition adds new growth platforms in **Women's Health** and **Biosimilars** and significantly expands Sun's global footprint.\n*   The transaction will be financed via cash and debt, increasing leverage to a pro-forma Net Debt\u002FEBITDA of **~2.3x** from a current net positive cash position.\n*   Management projects over **$350 Mn** in synergies, with the deal expected to close in **early 2027**.",{"company_name":98,"filing_date":105,"filing_source":9,"headline":106,"id":107,"stock_code":102,"summary_text":108},"2026-04-27T06:16:39.785000","Announces Acquisition of Organon & Co. and Schedules Investor Call","69eeb212f35e30561cff5a77","*   The company has announced the acquisition of Organon & Co., marking a significant strategic initiative.\n*   An investor call with senior management is scheduled for April 27, 2026, at 8:00 AM IST to discuss the acquisition.\n*   The call will provide updates on the valuation, strategic fit, and integration plan for the newly acquired asset.\n*   This material event was disclosed as an intimation under Regulation 30 of SEBI (LODR) Regulations, 2015.",{"company_name":98,"filing_date":110,"filing_source":9,"headline":111,"id":112,"stock_code":102,"summary_text":113},"2026-04-27T05:26:39.621000","To Acquire Organon & Co. for ~$4 Billion in All-Cash Deal","69eea671a157653c6639bce2","• Sun Pharma will acquire 100% of Organon & Co. (NYSE: OGN) in an all-cash transaction for an equity value of approximately $3.99 billion.\n• The deal values Organon at $14.00 per share, with a total enterprise value of approximately $11.75 billion.\n• This strategic acquisition will significantly expand Sun Pharma's portfolio into Women's Health and Biosimilars, enhancing its global scale.\n• Post-acquisition, the combined entity is projected to be a top 25 global pharma company with revenues of ~$12.4 billion.\n• The transaction is expected to close in early 2027, pending regulatory and stockholder approvals.",false,100,8,717]